TOP TEN perturbations for NM_000256 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000256
Selected probe(set): 208040_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000256 (208040_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

rheumatoid arthritis study 31 / TNF-? study 20

Relative Expression (log2-ratio):-1.706564
Number of Samples:4 / 3
Experimental rheumatoid arthritis study 31
Monocyte samples isolated from patients with rheumatoid arthritis (RA). Monocyte from whole blood were depleted from granulocytes by CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling. Patients fulfilled the revised American College of Rheumatology criteria (ACR) for RA.
Control TNF-? study 20
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNF? in whole blood for 1.5 hour. Following stimulation, monocyte were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling.

TNF-? study 20 / normal monocyte sample

Relative Expression (log2-ratio):1.3552456
Number of Samples:3 / 7
Experimental TNF-? study 20
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNF? in whole blood for 1.5 hour. Following stimulation, monocyte were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling.
Control normal monocyte sample
Monocyte samples isolated from healthy subjects. Peripheral blood monocytes were isolated immediately after drawing blood by depletion from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.3440123
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

TNF-? study 20 / unstimulated monocyte sample

Relative Expression (log2-ratio):1.2836208
Number of Samples:3 / 11
Experimental TNF-? study 20
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNF? in whole blood for 1.5 hour. Following stimulation, monocyte were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling.
Control unstimulated monocyte sample
Monocyte samples isolated from healthy donors and incubated in whole blood for 1.5 hour without any stimulation. Following incubation, monocyte were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.2722187
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1964521
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

immunoglobulin (IVIG) study 2 (responder) / Kawasaki disease study 2 (responder)

Relative Expression (log2-ratio):-1.1713123
Number of Samples:4 / 4
Experimental immunoglobulin (IVIG) study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:---
Control Kawasaki disease study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

asthma study 22 (eosinophilic AIP) / asthma study 22 (neutrophilic AIP)

Relative Expression (log2-ratio):-1.1501541
Number of Samples:15 / 17
Experimental asthma study 22 (eosinophilic AIP)
Sputum samples from asthmatic patients with eosinophilic airway inflammatory phenotype (AIP).
Control asthma study 22 (neutrophilic AIP)
Sputum samples from asthmatic patients with neutrophilic airway inflammatory phenotype (AIP).

asthma study 22 (neutrophilic AIP) / asthma study 22 (paucigranulocytic AIP)

Relative Expression (log2-ratio):1.1061192
Number of Samples:17 / 10
Experimental asthma study 22 (neutrophilic AIP)
Sputum samples from asthmatic patients with neutrophilic airway inflammatory phenotype (AIP).
Control asthma study 22 (paucigranulocytic AIP)
Sputum samples from asthmatic patients with paucigranulocytic airway inflammatory phenotype (AIP).

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.0169325
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.